Ardelyx, Inc.

Surrozen Operating, Inc.

Helene Baribault

Yang Li

Rakesh K Jain

Jason Gustaf Lewis

Wen-Chen Yeh

Jeremy Caldwell

Jianhua Chao

Lily Hu

Randall J Brezski

Tom Zhiye Yuan

Kuo-Pao Lai

Aaron Sato

Claudia Yvonne Janda

Zhengjian Zhang

Chenggang Lu

Tristan William Fowler

Shengjiang Tu

Leonard Presta

Hui Chen

Thomas Lopez

Liqin Xie

The present disclosure provides tissue-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in liver tissues.

Tissue-specific WNT signal enhancing molecules and uses

The present invention provides Wnt pathway agonists and related compositions, which may be used in any of a variety of therapeutic methods for the treatment of diseases.

Wnt surrogate molecules and uses thereof

The present disclosure provides liver-specific Wnt signal enhancing molecules, and related methods of using these molecules to increase Wnt signaling in liver tissues and treat liver diseases and disorders.

Liver-specific Wnt signal enhancing molecules and uses thereof

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L, A, X, X, R, R, and Rare described herein.

Hormone receptor modulators for treating metabolic conditions and disorders

WNT surrogate molecules and uses thereof

The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L, L, A, B, R, R, R, and Rare described herein.

Isoxazolyl-carbonyloxy azabicyclo[3.2.1]octanyl compounds as FXR activators

The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L, L, A, B, R, R, R, and Rare described herein. 

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L, A, X, X, R, R, and Rare described herein. 

Growing community of inventors

Fremont, CA, United States of America

Helene Baribault